Almahmeed, Wael A.
Hersi, Ahmad
Khalife, Natasha
Gamaleldin, Mohamed Fathy Soliman
Kherraf, Sid Ahmed
Sobhy, Mohamed A.
Lopes, Renato D.
Khoury, Maurice
Funding for this research was provided by:
Pfizer
Article History
Received: 5 April 2024
Accepted: 7 May 2024
First Online: 27 May 2024
Declarations
:
: Ahmad Hersi received honoraria from Pfizer Inc. for giving talks and workshops. Mohamed A. Sobhy and Maurice Khoury have no conflicts to disclose. Wael A. Almahmeed is on the Pfizer Advisory board for the study. Natasha Khalife is an employee of IQVIA, which conducted the study on behalf of the sponsor. Mohamed Fathy Soliman Gamaleldin and Sid Ahmed Kherraf are employees of Pfizer Inc., the study sponsor. Renato D. Lopes reports research grants or contracts from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, Sanofi-Aventis; funding for educational activities or lectures from Pfizer, Bristol-Myers Squibb, Novo Nordisk, AstraZeneca, and funding for consulting from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Novo Nordisk, AstraZeneca.
: Institutional review board (IRB) approvals were obtained. Table in the Supplementary Material provides the list of IRBs and corresponding protocol approval dates. The registry was conducted in accordance with the principles of the Declaration of Helsinki, local regulatory requirements, and the International Conference on Harmonisation-Good Pharmacoepidemiological and Clinical Practice guidelines. In addition, written informed consent was obtained from all study participants and confidentiality and anonymity of all patients recruited into this registry were maintained.